FDA proposes infant-formula nutrient changes in first phase of review

The U.S. Food and Drug Administration has proposed changing specifications for four nutrients in infant formula and revising the label units for two vitamins as part of the first phase of a wider review. The agency says that phase covers eight of the 30 nutrients currently required in formula.

In its proposal summary, FDA identifies iodine, manganese and vitamins A and D as the nutrients whose specifications it proposes to change. It proposes retaining the existing specifications for chloride, potassium, selenium and sodium. Those two groups make up the eight nutrients in this first phase; the summary does not establish the eventual decisions for the remaining nutrients.

The proposed label-unit changes concern vitamins A and D. They are a separate part of the proposal from the specification changes for those vitamins. FDA describes both as proposed changes, not requirements that have already taken effect.

The agency is also seeking input on possible additional nutrient requirements. At the same time, it says this particular proposal neither adds to nor removes from the list of required nutrients. The request for input leaves a question open; it does not establish that an additional requirement has been adopted.

FDA describes three review phases and says it intends to combine eventual changes into one later final rule. The agency dates the proposed action to October 29, 2026. The material reviewed for this report does not establish a Federal Register publication date or a comment deadline, and the agency’s intention does not settle the contents or timing of a final rule. This account relies on FDA’s summary; the full proposed rule and underlying scientific studies were not examined for this report.

Mira Vale analysis: The agency’s description brings three distinct issues into view: nutrient specifications, the units used to express two vitamins on labels, and a later decision on a final rule. A proposal on the first two should not be treated as proof that the third has been settled. FDA can also ask for ideas on possible additional requirements while leaving the required nutrient list unchanged in this proposal. Keeping those questions apart helps readers see what is under consideration and what remains for later decisions.